EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Hypoimmune CD19 CAR T cells evade allorejection in patients with cancer and autoimmune disease

Xiaomeng Hu, Pascal Beauchesne, Chenyan Wang, Athena Wong, Tobias Deuse, Sonja Schrepfer, ARDENT and GLEAM investigators

Cell Stem Cell · 2025-09 · 32 (9) · 1356-1368.e4

DOI: 10.1016/j.stem.2025.07.009 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cell Stem Cell, 2025-09. Verfasst von Xiaomeng Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sana Biotechnology Inc., 1 Tower Place, South San Francisco, CA, USA. Hauptthemen laut MEDLINE: Antigens, CD19, Autoimmune Diseases, Immunotherapy, Adoptive, Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Off-the-shelf CAR T cells need to reliably escape allogeneic immune responses to become universal medicines. The primary T cell product SC291 was engineered with a CD19 CAR, T cell receptor alpha constant (TRAC) knockout, and the hypoimmune (HIP) edits of HLA depletion and CD47 overexpression. Here, we report exploratory immune analyses from the ARDENT (NCT05878184) and GLEAM (NCT06294236) trials with HIP-edited CD19 CAR T cells. Although there was an alloimmune response against HLA-replete subpopulations of SC291, we observed no de novo immune response against fully edited HIP CAR T cells in all patients, irrespective of the dose or the patient's disease. The lack of antibodies against the HLA-replete CAR T cells was identified as a marker for deep tissue CD19 cell depletion, and all patients without such antibodies for 60 days showed concomitant B cell depletion in peripheral blood. The immune data presented support the reliability of the HIP concept to evade allorejection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, CD19Autoimmune DiseasesImmunotherapy, AdoptiveNeoplasmsReceptors, Chimeric AntigenT-LymphocytesFemaleHumansMaleMiddle AgedReceptors, Antigen, T-Cell

Stichwörter der Autor:innen

clinical trialhypoimmunerejection

Substanzen

Antigens, CD19Receptors, Antigen, T-CellReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Sana Biotechnology Inc., 1 Tower Place, South San Francisco, CA, USA.
  • Sana Biotechnology Inc., 1 Tower Place, South San Francisco, CA, USA. Electronic address: sonja.schrepfer@sana.com.

Zitieren

APA

Hu, X., Beauchesne, P., Wang, C., Wong, A., Deuse, T., Schrepfer, S., & ARDENT and GLEAM investigators (2025). Hypoimmune CD19 CAR T cells evade allorejection in patients with cancer and autoimmune disease. Cell Stem Cell, 32(9), 1356-1368.e4. https://doi.org/10.1016/j.stem.2025.07.009

Vancouver

Hu X, Beauchesne P, Wang C, Wong A, Deuse T, Schrepfer S, et al. Hypoimmune CD19 CAR T cells evade allorejection in patients with cancer and autoimmune disease. Cell Stem Cell. 2025;32(9):1356-1368.e4. doi:10.1016/j.stem.2025.07.009

BibTeX
@article{Hu2025,
  author = {Hu, Xiaomeng and Beauchesne, Pascal and Wang, Chenyan and Wong, Athena and Deuse, Tobias and Schrepfer, Sonja and ARDENT and GLEAM investigators, ARDENT and GLEAM investigators},
  title = {Hypoimmune CD19 CAR T cells evade allorejection in patients with cancer and autoimmune disease},
  journal = {Cell Stem Cell},
  year = {2025},
  volume = {32},
  number = {9},
  pages = {1356--1368.e4},
  doi = {10.1016/j.stem.2025.07.009}
}
Kostenlos starten →